FRM
OCUL icon

Fox Run Management’s Ocular Therapeutix OCUL Stock Holding History

Fox Run Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81.1K Sell
10,955
-42,137
-79% -$402K 0.01% 848
2025
Q4 		$645K Buy
+53,092
New +$645K 0.1% 392
2022
Q4 		– Sell
-25,597
Closed -$106K – 810
2022
Q3 		$106K Buy
+25,597
New +$129K 0.04% 545
2022
Q1 		– Sell
-12,752
Closed -$89K – 644
2021
Q4 		$89K Buy
+12,752
New +$99K 0.05% 426

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fox Run Management's OCUL Position: Q1 2026 in Review

Fox Run Management reduced its Ocular Therapeutix (OCUL) stake by 79% in Q1 2026, selling an estimated $402K and leaving 10,955 shares worth $81.1K. The position accounts for 0.01% of the portfolio, ranked #848.

Fox Run Management first reported a position in OCUL in Q4 2021 and has held it in 4 quarters since. The position peaked at $645K in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Fox Run Management held 10,955 shares of Ocular Therapeutix worth $81.1K as of Q1 2026.
  • Fox Run Management sold 42,137 Ocular Therapeutix shares in Q1 2026, an estimated $402K.
  • Ocular Therapeutix made up 0.01% of Fox Run Management's portfolio in Q1 2026, its #848 holding.
  • Fox Run Management first reported a position in Ocular Therapeutix in Q4 2021 and has held it in 4 quarters since.
  • Fox Run Management's Ocular Therapeutix position peaked at $645K in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.